Vor Biopharma Inc（VOR）财务数据VORVor Biopharma Inc

In the context of the broader market, VOR competes directly with industry leaders such as REPL and JANX. With a market capitalization of $1.12B, it holds a significant position in the sector. When comparing efficiency, VOR's gross margin of N/A stands against REPL's N/A and JANX's 100.00%. Such benchmarking helps identify whether Vor Biopharma Inc. is trading at a premium or discount relative to its financial performance.

Vor Biopharma has shown a significant reduction in R&D expenses, down to $25.9 million in Q2 2026 from $261.5 million in Q2 2025, indicating improved cost management. However, the company has reported substantial losses, including a net income loss of $1.57 billion in Q2 2025.